Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Đánh giá toàn diện về mối liên hệ giữa biến thể Thr241Met của gen sửa chữa DNA XRCC3 và nguy cơ mắc bệnh bạch cầu
Tóm tắt
Gen XRCC3 đã được gợi ý đóng vai trò quan trọng trong cơ chế bệnh sinh của nguy cơ mắc bệnh bạch cầu. Tuy nhiên, các phát hiện từ các tạp chí công bố lại mâu thuẫn với nhau. Để đưa ra ước lượng chính xác hơn về mối liên hệ này, chúng tôi đã thực hiện một phân tích tổng hợp. Các cơ sở dữ liệu PubMed, Embase và Cơ sở hạ tầng tri thức quốc gia Trung Quốc (CNKI) đã được tìm kiếm cho các nghiên cứu trường hợp – chứng có mặt từ tháng 8 năm 2013. Tỉ lệ odds tổng hợp (OR) và khoảng tin cậy 95% (CI) tương ứng đã được tính toán bằng cách sử dụng mô hình hiệu ứng cố định hoặc ngẫu nhiên. Tổng cộng có 15 nghiên cứu trường hợp- chứng đã đáp ứng tiêu chí lựa chọn và được chọn. Tỉ lệ OR tổng hợp cho thấy không có mối liên hệ có ý nghĩa thống kê giữa biến thể Thr241Met của XRCC3 và nguy cơ mắc bệnh bạch cầu trong tất cả các nghiên cứu, trong khi một mối liên hệ có nguy cơ đã được quan sát thấy đối với bệnh bạch cầu cấp dòng tủy (AML) (mô hình chính TT/TC so với CC: OR = 1.240, 95% CI = 1.018–1.511, P = 0.032). Biến thể Thr241Met của XRCC3 có thể liên quan đến nguy cơ mắc bệnh bạch cầu ở AML. Cần có thêm nhiều nghiên cứu với kích thước mẫu lớn hơn để xác nhận kết quả này.
Từ khóa
#gen XRCC3 #biến thể Thr241Met #nguy cơ bạch cầu #bệnh bạch cầu cấp dòng tủy #phân tích tổng hợpTài liệu tham khảo
Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4:270–90.
Advani AS, Hunger SP, Burnett AK. Acute leukemia in adolescents and young adults. Semin Oncol. 2009;36:213–26.
Meenaghan T, Dowling M, Kelly M. Acute leukaemia: making sense of a complex blood cancer. Br J Nurs. 2012;21(76):78–83.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH, et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002;99:1909–12.
Siddon AJ, Rinder HM. Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. Am J Clin Pathol. 2013;139:708–12.
Ilhan G, Karakus S, Andic N. Risk factors and primary prevention of acute leukemia. Asian Pac J Cancer Prev. 2006;7:515–7.
Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137:S68–97.
Preston DL, Pierce DA, Shimizu Y, et al. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res. 2004;162:377–89.
Lee SA, Lee KM, Park SK, et al. Genetic polymorphism of xrcc3 thr241met and breast cancer risk: case–control study in Korean women and meta-analysis of 12 studies. Breast Cancer Res Treat. 2007;103:71–6.
Tebbs RS, Zhao Y, Tucker JD, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci U S A. 1995;92:6354–8.
Griffin CS. Aneuploidy, centrosome activity and chromosome instability in cells deficient in homologous recombination repair. Mutation research. 2002;504:149–55.
Romanowicz-Makowska H, Brys M, Forma E, et al. Single nucleotide polymorphism (SNP) Thr241Met in the XRCC3 gene and breast cancer risk in Polish women. Pol J Pathol. 2012;63:121–5.
Banescu C, Tilinca M, Benedek EL, et al. XRCC3 Thr241Met polymorphism and risk of acute myeloid leukemia in a Romanian population. Gene. 2013;526:478–83.
Krupa R, Sliwinski T, Wisniewska-Jarosinska M, et al. Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer—a case control study. Mol Biol Rep. 2011;38:2849–54.
Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.
Matullo G, Guarrera S, Carturan S, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889–94.
Attia J, Thakkinstian A, D’Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 470–461.
Yang L, Xu SC, Liu XP. Relationship between GSTT1, GSTM1, NQO1, RAD51 and XRCC3 genes polymorphisms and chronic myeloid leukemia. Inter J Blood Transf Hemat. 2006;29:2–5.
Liu L, Yang L, Mi Y, et al. Rad51 and XRCC3 polymorphism: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/cbfbeta-myh11(+) acute myeloid leukemia. Leuk Res. 2011;35:1020–6.
Yang L, Liu L, Mi YC. Relationship between rad51–g135c/xrcc3–c241t polymorphisms and development of acute myeloid leukemia with recurrent chromosome translocation. Zhonghua xue ye xue za zhi. 2011;32:299–303.
Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10:2675–80.
Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100:3761–6.
Sorour A, Ayad MW, Kassem H. The genotype distribution of the XRCC1, XRCC3, and XPD DNA repair genes and their role for the development of acute myeloblastic leukemia. Genet Test Mol Biomarkers. 2013;17:195–201.
Abramenko I, Bilous N, Chumak A, et al. DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of Chernobyl nuclear power plant accident. J Radiat Res. 2012;53:497–503.
Hamdy MS, El-Haddad AM, Bahaa El-Din NM, et al. RAD51 and XRCC3 gene polymorphisms and the risk of developing acute myeloid leukemia. J Investig Med. 2011;59:1124–30.
Bhatla D, Gerbing RB, Alonzo TA, et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the children’s oncology group. Leukemia. 2008;22:265–72.
Guillem VM, Collado M, Terol MJ, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia. 2007;21:1413–22.
Voso MT, Fabiani E, D’Alo F, et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol. 2007;18:1523–8.
Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006;27:997–1007.
Zhang ZQ, Yang L, Zhang Y. Relationship between NQO1C(609T), RAD51(G135C), XRCC3(C241T) single nucleotide polymorphisms and acute lymphoblastic leukemia. Zhongguo shi yan xue ye xue za zhi. 2009;17:523–8.
Yang L, Zhang MR, Zhang Y. Relationship of RAD51–G135C and XRCC3–C241T polymorphisms with acute myeloid leukemia, myelodysplastic syndromes and karyotype abnormalities. Zhonghua xue ye xue za zhi. 2006;27:727–31.
Mitchell AA, Cutler DJ, Chakravarti A. Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. Am J Hum Genet. 2003;72:598–610.
Hosking L, Lumsden S, Lewis K, et al. Detection of genotyping errors by Hardy–Weinberg equilibrium testing. Eur J Hum Genet. 2004;12:395–9.
Garcia-Closas M, Malats N, Real FX, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.